ABC | Volume 113, Nº3, September 2019

Case Report Cilsal Single-ventricle atrioventricular connection in elderly individual Arq Bras Cardiol. 2019; 113(3):438-443 1. Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, et al. Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013;128(3):281-308. 2. Wood JC, Enriquez C, GhugreN, Otto-Duessel M, Aguilar M, NelsonMD, et al. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci. 2005;1054:386-95. 3. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, eds. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 3rd ed. Nicosia (CY): Thalassaemia International Federation; 2014. 4. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta- thalassemiamajor patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-44. 5. Wood JC. Cardiac complications in thalassemia major. Hemoglobin. 2009;33(Suppl1):S81-6. 6. Aessopos A, Farmakis D, KaragiorgaM, Voskaridou E, Loutradi A, Hatziliami A, et al. Cardiac involvement in thalassemia intermedia: amulticenter study. Blood. 2001;97(11):3411-6. 7. Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, et al. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail. 2010;3(3):451-8. 8. Hahalis G, Manolis AS, Gerasimidou I, Alexopoulos D, Sitafidis G, Kourakli A, et al. Right ventricular diastolic function in beta- thalassemia major: echocardiographic and clinical correlates. Am Heart J. 2001;141(3):428-34. 9. Lang RM, American Society of Echocardiography. Dynamic echocardiography. 1st ed. St. Louis, Mo.: Saunders/Elsevier; 2011. 10. Taber M, Askenazi J, Ribner H, Kumar S, Lesch M. The tricuspid valve in carcinoid syndrome. An echocardiographic study. Arch Intern Med. 1983;143(5):1033-4. Referências This is an open-access article distributed under the terms of the Creative Commons Attribution License dysfunction due to myocardial involvement, and severe leaflet disorder due to valvular involvement. We herein report an extraordinary thalassemia major patient with immobile and non-stenotic tricuspid valve that emerges as a part of the terminal phase of the cardiomyopathy. Conclusion Thalassemia major patients, especially those who do not receive regular chelation therapy, are under great risk of cardiac involvement. Early detection and regular treatment regimen enhance their survival and quality of life. We firstly present an immobile tricuspid valve in an adolescent girl. This very rare case of severe cardiac findings due to iron deposition is associated with endocardial, myocardial and valvular involvement. In patients with thalassemia, these end-stage complications of the cardiovascular system are irreversible despite treatment. Author contributions Conception and design of the research, Acquisition of data, Analysis and interpretation of the data, Writing of the manuscript abnd Critical revision of the manuscript for intellectual content: Cilsal E. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This study is not associatedwith any thesis or dissertationwork. 443